Background-We investigated the long-term impact of different stent types and diabetes mellitus (DM) 
C oronary artery disease in diabetes mellitus (DM) patients is described as being diffuse and typically presents a rapid progression. 1 Revascularization procedures in these patients are usually associated with worse outcomes and increased rates of restenosis than those performed in patients without DM. [2] [3] [4] [5] Drug-eluting stents (DES) have been shown to be more effective than bare metal stents (BMS) in DM patients with coronary lesions of low to moderate risk, 6 -9 but little is known about more complex scenarios, such as bifurcation lesions.
Clinical Perspective on p 79
Bifurcation lesions account for up to 20% of all coronary lesions that require percutaneous coronary intervention (PCI) in high volume centers. 10 Because of their high potential for restenosis, 11 the use of DES in bifurcation lesions is expected to be associated with a dramatic early efficacy in reducing the need for revascularization compared with BMS. On the downside, the combination of DM and DES bifurcation stenting is also a potential trigger for stent thrombosis, [12] [13] [14] and whether this concern may translate into worse outcomes over time has not been widely explored.
To shed more light on the relative benefits of using different stent types for DM patients with coronary bifurcation lesions submitted to PCI in a real-world setting, we investigated the 3-year clinical outcomes recorded in a large multicenter registry.
Methods

Study Population
The Societa' Italiana di Cardiologia Invasiva-Gruppo Italiano Studi Emodinamici (SICI-GISE) survey on bifurcation lesions (I-BIGIS) is a retrospective, observational multicenter registry promoted by the Italian Society of Invasive Cardiology independent of commercial funding. Twenty-two participating centers (see online 15 Eligibility for 1-year follow-up was required to be included in the registry, but no specific exclusion criteria were adopted. Individuals receiving both DES and BMS during the index admission or balloon angioplasty (POBA) on both branches, as well as those with unknown DM status, were excluded from this prespecified analysis. Diabetes was defined according to the World Health Organization Report. 16 Although follow-up extended beyond 3 years for mortality in a proportion of patients at the time of data analysis, we restricted the follow-up to 3 years in all patients to account for bias introduced by incomplete follow-up.
Study Design and Data Collection
Of the 247 Italian catheterization laboratories officially constituting the SICI-GISE that were invited to join the registry, 22 centers were included in the final analysis. Minimum requirements were the routine performance of PCI, DES availability, and dedicated procedural database throughout the study period. Main reasons of exclusion were the absence of a procedural electronic database and/or systematic clinical follow-up. To avoid selection biases or incomplete data reports, centers without clinical follow-up rate Ͼ90% were also not included in the registry.
By design, the SICI-GISE Italian I-BIGIS survey used a dedicated database for data entry, explicit definitions for baseline and procedural characteristics, and clinical-event, committee-based, end-point adjudication. The coordinating center was involved in collection, source verification and quality control of the data, with oversight by an independent clinical events committee (E.R., G.M.S.). Because of the retrospective and observational nature of the study, treatment strategy, stent selection and postprocedural management were left to the operator/center practice. All patients signed informed consent forms regarding the procedure and data collection. In particular, patients were discharged after the procedure on oral thienopyridines for 3 to 12 months plus aspirin indefinitely, at the discretion of the operator. Information concerning in-hospital events was obtained from centralized databases of the participating institutions for those patients who stayed in local hospitals and from the hospital records or by telephone contacts for those transferred to another hospital after the procedure. Clinical follow-up data related to medications and clinical status were prospectively collected through scheduled outpatient clinic evaluations. Referring cardiologists, general practitioners, and patients were contacted whenever necessary for further information. All repeated coronary intervention (surgical and percutaneous) and rehospitalization data were prospectively collected during follow-up using the centralized system of the participating institution or by directly contacting the hospitals where the patients were admitted or referred.
Clinical Outcomes and Definitions
Primary outcome end-point was the 3-year rate of major adverse cardiovascular events (MACE) defined as the composite of cardiac death, Q-wave and non-Q-wave myocardial infarction (MI), and target lesion revascularization (TLR).
Bifurcation lesion was defined as visually estimated presence of Ͼ50% diameter stenosis in major epicardial coronary vessel involving coronary bifurcation with a reference vessel between 2.5 mm and 4.5 mm in diameter for the main branch and between 2.25 mm and 4.5 mm for the side branch. True coronary bifurcation lesion was defined as a stenosis Ͼ50% in both the main branch and the ostium of the side branch, based on the Medina classification. 17 Cardiac death was defined as any death due to cardiac cause (ie, MI, low-output failure, and fatal arrhythmia), procedure-related deaths, and death of unknown cause. MI was defined as Q-wave MI in the presence of new pathological Q waves on the ECG in Ն2 contiguous leads or non-Q-wave MI in presence of an elevation of creatine kinase level or its MB isoenzyme to Ն2 the upper normal limit. 18 TLR was defined as any revascularization procedure (angioplasty, stenting, or coronary artery bypass surgery) performed because of angiographic restenosis at the site of the bifurcation treated (within the stent or 5 mm proximal or distal to it) associated with clinical and/or objective evidence of inducible myocardial ischemia.
Stent thrombosis rates were assessed according to the Academic Research Consortium (ARC) definition 19 as definite, probable, or possible and as acute, subacute, late, or very late. The definition of definite stent thrombosis required the presence of an acute coronary syndrome with angiographic or autopsy evidence of in-stent thrombus or occlusion. Probable stent thrombosis included unexplained deaths within 30 days after the procedure or acute MI involving the target-vessel territory without angiographic confirmation. Possible stent thrombosis included all unexplained deaths occurring at least 30 days after the procedure. 19 
Statistical Analysis
Between-group comparisons were done with the 2 test for categorical variables and the unpaired t test or the nonparametric MannWhitney rank sum test for continuous variables based on the normality (Kolmogorov-Smirnov test) of the data. Two-sided 95% confidence intervals (CIs) were calculated for thrombosis rates as the difference between groups Ϯ1.96 SE of the difference. A PϽ0.05 cutoff was used to indicate significance. Unadjusted 3-year KaplanMeier estimates were provided for clinical outcomes. Patients lost to follow-up were considered at risk until the date of last contact, at which point they were censored.
Control of potential confounders was attempted by performing a Cox multivariable proportional hazard regression analysis to estimate the independent effect of stent type (DES or BMS) in both DM and non-DM patients. To avoid overfitting, selection of the logistic and Cox multivariable regression models was done with backward elimination (Wald statistic, confirmed using forward and stepwise selection) based on variables listed in Table 1 and 2 and considered first-order interactions between variables that were univariately associated with the variable of interest. A PϽ0.05 significance level was used for model inclusion and PϾ0.10 for exclusion. The assumption of the proportional hazard was verified and highly redundant variables were avoided. The variables finally considered and entered in the model for adjustment in the stent-type analysis by DM status included the following: (1) for non-DM patients: prior MI, prior PCI, left ventricular ejection fraction (LVEF) Ͻ 50%, coronary artery disease involving left main bifurcation, coronary artery disease involving left anterior descending bifurcation, in-stent restenosis, technique change required during PCI, main branch stent diameter, side branch stent length and intravascular ultrasound (IVUS) guidance as independent control variables, and treatment group (DES versus BMS) as independent study variable of interest; (2) for DM patients: LVEF Ͻ50%, multivessel coronary artery disease and side branch stent length as independent control variables and treatment group (DES versus BMS) as independent study variable of interest. The performance of each model was investigated by means of the Hosmer-Lemeshow goodness of fit test and judged satisfactory in all cases. All statistical analyses were performed using the Statistical Package for Social Sciences (SPSS) version 15.0 (SPSS Inc., Chicago, IL).
Results
A total of 1049 DM and 3020 non-DM patients undergoing bifurcation PCI entered this analysis (Figure 1 ). Based on the study definitions, 182 of 854 patients who received a BMS (21%) and 867 of 3215 patients who received a DES (27%) had diabetes.
Baseline Patient Characteristics
Details on baseline clinical characteristics stratified by DM status and stent type are listed in Table 1 . Among DM patients, those treated with DES were younger and more likely to have chronic renal failure (defined as creatinine Ͼ1.7 mg/dL) and history of prior MI and PCI. Conversely, admission for acute MI was more common in DM patients treated with BMS. Among non-DM patients, differences between those treated with DES and those treated with BMS were more pronounced. Patients treated with DES were younger and more likely to be hyperlipidemic and smokers, as well as to present with a history of previous MI, PCI, and CABG. Once again, admission for acute MI was more common in patients treated with BMS. Table 2 reports details on lesion and procedural characteristics. Among DM patients, both branches were stented in 38% of lesions treated with DES and 16% of lesions treated with BMS (PϽ0.001). Mean stent diameter of the main branch was lower and stent length was longer in bifurcations treated with DES. Final kissing balloon inflation (57.6% versus 33.3%, PϽ0.001) and IVUS guidance (5.8% versus 1.1%, Pϭ0.007) were less common among patients treated with BMS.
Angiographic and Procedural Characteristics
Similar unbalances between stent types were observed among non-DM patients. However, unlike in DM patients, true bifurcations and in-stent restenosis were more frequent in patients treated with DES. Almost half of patients treated with DES in both groups were still on dual antiplatelet therapy at 12 months versus Ϸ25% of those treated with BMS.
Midterm and Long-Term Follow-Up
Clinical follow-up was available at a mean of 736Ϯ456 days and a median of 671 (Q1 388, Q3 998) days. Complete 1-year outcome data were available in 93% of patients. Outcomes of patients stratified by DM status and stent type are reported in Figure 2 and Table 3 . At 3 years, in the group of DM patients, those treated with DES had lower 3-year Kaplan-Meier estimates of MACE (26.0% versus 31.7%) and cardiac death (9.4% versus 12.9%) compared with those treated with BMS, whereas no relevant differences were seen in terms of MI (6.7% versus 6.1%). A trend toward more TLR was seen with BMS compared with DES (21.4% versus 24.2%). After adjustment for potential confounders, DES were found to be associated with a lower 3-year risk of MACE (adjusted HR 0.27, 95% CI 0.15 to 0.49, PϽ0.001), cardiac death (adjusted HR 0.09, 95% CI 0.03 to 0.21, PϽ0.001), and TLR (adjusted HR 0.30, 95% CI 0.16 to 0.59, Pϭ0.001), whereas no differences were found in terms of MI (Figure 3) . Importantly, DES displayed a lower risk of MACE than BMS in DM patients not on insulin therapy (23.3% versus 29.8%, adjusted HR 0.20, 95% CI 0.10 to 0.39, PϽ0.001), whereas comparable outcomes between stent types were observed in DM patients on insulin (32.5% versus 34.5%, adjusted HR 0.74, 95 CIs 0.22 to 2.48, Pϭ0.63).
Among non-DM patients, there were no differences in the unadjusted 3-year rates of MACE (16.5% versus 18.1%), car- Incidence of major adverse cardiac events for stent type stratified by diabetes status. Regardless of stent type, diabetic patients with bifurcation lesions had worse long-term outcomes than those who were non-diabetic. BMS indicates bare metal stent; DES, drug eluting stent; DM, diabetes mellitus. diac death (5.1% versus 5.5%), MI (5.1% versus 3.7%), and TLR (11.8% versus 13.7%). Consistently, after adjustment, no differences were noted regarding the 3-year risk of MACE and subcomponent end points between DES and BMS ( Figure 3 ).
Stent Thrombosis
Stent thrombosis rates observed in DM patients at several time points according to the ARC definitions are listed in Table 3 . Overall, patients treated with DES or BMS had comparable rates of any (4.2% versus 4.4%) and definite/ probable (2.7% versus 2.2%) stent thrombosis.
Discussion
Bifurcation lesions represent a challenge for the interventional cardiologist. A number of well-known technical and clinical issues are associated with this subset, depending on the anatomy, lesion, and stenting technique. Axial plaque redistribution after PCI of lesions located next to a coronary bifurcation almost inevitably causes plaque shifting in the side branches, and that makes these lesions particularly demanding. Diabetes has a well-established impact on the long-term outcome following PCI, being per se a major risk factor for restenosis and death. [3] [4] [5] Despite the important role of stenting in bifurcation lesions and DM patients, there has been limited information on the long-term safety and efficacy of DES use in this scenario.
The present study demonstrated that, in DM patients with coronary bifurcation lesions, stenting with DES yields improved long-term outcomes compared with BMS. After adjustment for potential confounders, the use of DES was associated with a 73% risk reduction of MACE. This effect was significantly noted only in non-insulin-treated subjects, thus suggesting that more advanced stages of diabetes may have the potential to offset the efficacy of DES. 20 Differences in the primary end point were driven by a significantly lower rate of repeat revascularization and a remarkable benefit in terms of mortality. Owing to the nonrandomized nature of this observational study, either identified or unidentified confounders may have contributed to the observed difference in mortality between DES and BMS. Although a formal backward elimination did not identify ST-elevation MI as a potential confounder for multivariable adjustment, it should be emphasized that patients presenting with acute myocardial infarction due to a bifurcation culprit lesion were more likely to be treated with BMS than DES both in DM and non-DM subjects. While the advantage of DES over BMS in reducing mortality was consistent even after forcing acute myocardial infarction in the multivariate model, caution should be applied when interpreting these results. The admitted potential for residual confounding is also suggested by the unexpected observation that the presumptive benefits of DES in reducing mortality were not driven by substantial reduction in MI. This latter finding is puzzled by the chosen definition of MI, which did not take into account only reinfarction related to the target vessel. That being said, our results outline that, in DM patients with high-risk coronary artery disease, such as Figure 3 . Adjusted clinical outcomes for stent type stratified by diabetes status. In diabetic patients with coronary bifurcation lesions, the use of DES is associated with a significant reduction of MACE with differences in the primary end-point driven by a significant lower risk of repeat revascularization and cardiac death. These findings do not significantly apply to non-diabetic patients. DES indicates drug eluting stent; DM, diabetes mellitus; MACE, major adverse cardiac events.
those with bifurcation lesions, the well-known efficacy of DES is not associated with worse outcomes and possibly translates into improved survival compared with BMS. The hypothesis that DES leads to improved survival in this very challenging subset of lesions is plausible and consistent with a meta-analysis of Ϸ150 000 patients from observational studies of DES versus BMS, 21 but it has never been specifically investigated in a large population of patients with bifurcation lesions. It is also important to note that both DM and bifurcation lesions have been shown to be associated with stent thrombosis; [12] [13] [14] and therefore, their combination has the potential of being a powerful determinant of adverse outcomes. This study reported comparable rates of stent thrombosis between DES and BMS, both in terms of any ARC (4.2% versus 4.4%) or definite/probable (2.7% versus 2.2%) stent thrombosis. Overall, our results outline that DES represents safe and effective devices for stenting of bifurcation lesions in DM patients.
Unlike with DM patients, DES failed to show their longterm superiority to BMS in patients without DM, suggesting a less favorable balance between safety and efficacy in a simpler scenario. This is in agreement with a study showing that patients who benefit most from DES in terms of net clinical outcome are those at higher risk of restenosis, including patients with diabetes. 22 Of note, DM patients with bifurcation lesions had worse long-term outcomes than patients without, regardless of stent type, consistently with other PCI settings. 23, 24 In fact, DM is characterized by a variety of mechanisms responsible for accelerated atherosclerosis affecting the entire coronary circulation, 25, 26 and DES does not address nontarget lesions related to disease progression and plaque rupture. These data in aggregate corroborate the understanding that the beneficial effect of DES observed in clinical trials may result as the balance between dramatic improvements in clinical outcomes of complex subgroups and less significant advantages observed in patients at lower risk.
Limitations
The most important limitation of the present study is the lack of a random assignment to treatment groups. Evaluating the impact of a specific treatment using a registry can lead to incorrect conclusions because of the influence of unassessed confounding variables (eg, comorbidities, terminal illness, low socioeconomic status). In this study, each treatment was not assigned randomly but by specific criteria in each case, generating an unavoidable risk of bias regarding treatment selection and the possible prognosis. To compensate in part for the baseline and angiographic imbalance between groups, we performed adjustment with multivariate analysis to make residual selection biases unlikely. However, it is impossible to know whether this adjustment is appropriate or whether the relevant characteristics have been correctly identified, because only randomization can provide an unbiased estimation of the effects of a treatment. Another caveat is that outcomes were not stratified based on the 6 categories of the Medina classification. However, we assessed the impact of true bifurcations (Medina 1,1,1) over nontrue bifurcations and found no significant interaction with stent type.
Conclusions
In a large, real-world patient population undergoing PCI and stenting of coronary bifurcation lesions, the use of DES in DM patients was associated with improved outcomes in terms of MACE, cardiac death, and repeat revascularization at long-term follow-up, thus suggesting a favorable balance between efficacy and safety in this very complex scenario.
Sources of Funding
The registry was an investigator-driven clinical study conducted by the Italian Society of Invasive Cardiology (SICI-GISE) and thus independent of commercial funding.
